Skip to search formSkip to main contentSkip to account menu

ESHAP protocol

Known as: Cisplatin/Cytarabine/Etoposide/Methylprednisolone, ARA-C/CDDP/MePRDL/VP-16, E-SHAP 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Introduction: 30% of Hodgkin Lymphoma (HL) patients are refractory or relapse (RR) after first line therapy. Salvage chemotherapy… 
2016
2016
The management of recurrent/refractory (R/R) Hodgkin lymphoma (HL) remains challenging. Previously published data have shown some… 
2010
2010
BACKGROUND Treatment for refractory lymphoma in frail patients (older, poor performance status, or concomitant diseases) has not… 
Review
2004
Review
2004
The prognosis is poor for patients relapsing following treatment with standard chemotherapy for aggressive non-Hodgkin's lymphoma… 
Highly Cited
2002
Highly Cited
2002
Treatment for patients with stage IV indolent lymphoma ranges from watchful waiting to intensive chemotherapy and stem cell… 
1999
1999
This study was designed to assess the results of protracted courses of ESHAP (etoposide, cytarabine, cisplatin… 
1996
1996
There are few reports of salvage chemotherapy for HIV-related non-Hodgkin's lymphoma (NHL). We report a relapsed HIV-related high…